Julien's Primer of Drug Action by Claire D. Advokat; Joseph E. Comaty; Robert M. Julien - Fourteenth Edition, 2019 from Macmillan Student Store
star icon

FREE shipping.

Promo Code SHIPFREE

Julien's Primer of Drug Action

Fourteenth  Edition©2019 Claire D. Advokat; Joseph E. Comaty; Robert M. Julien

About

Julien’s Primer of Drug Action continues to evolve side by side with the field it covers providing a thoroughly up to date look at psychotherapeutic and recreational drugs, including the latest research and the newest formulations. 

The thoroughly updated 14th edition features:

  • New coverage of opioids of abuse, and  drugs used to treat of opioid dependence and opioid overdose.
  • New research on the use of marijuana to treat Alzheimers, PTSD,  and Epilepsy.  
  • New coverage of pharmacological, physiological, and psychoactive effects  of synthetic marijuana including its toxicity.
  • New research on Cannabidiol (CBD) and its therapeutic uses
  • New research of the efficacy of  antipsychotics to treat  dementia, Parkinson’s, bipolar, OCD, PTSD,
  • New research on hallucinogenics for the treatment of various disorders including MDMA for the treatment of PTSD, Psilocybin for treatment of depression and end-of-life anxiety, and Ayahuasca to treat psychiatric disorders
  • The use of genetic testing to predict effectiveness of  antidepressant treatment
  • New research on the use of ketamine for the treatment of depression

 

Table of Contents

Part 1 Introduction to Psychopharmacology: Biological Basis of Drug Action
Chapter 1 Pharmacokinetics: How Drugs Are Handled by the Body
Chapter 2 The Neuron, Synaptic Transmission, and Neurotransmitters
Chapter 3  Pharmacodynamics: How Drugs Act

Part 2 Pharmacology of Drugs of Abuse 93
Chapter 4  Epidemiology and Neurobiology of Addiction
Chapter 5  Ethyl Alcohol and the Inhalants of Abuse
Chapter 7  Cocaine, the Amphetamines, and Other Psychostimulants
Chapter 8  Psychedelic Drugs
Chapter 9 Cannabis:  A New Look at An Ancient Plant
Chapter 10 Opioid Analgesics

Part 3 Psychotherapeutic Drugs
Chapter 11  Antipsychotic Drugs
Chapter 12  Antidepressant Drugs
Chapter 13  Anxiolytics, Sedative Hypnotics, Anesthetics, and Anticonvulsants
Chapter 14  Drugs Used to Treat Bipolar Disorder

Part 4 Special Populations and Integration
Chapter 15  Child and Adolescent Psychopharmacology
Chapter 16  Geriatric Psychopharmacology
Chapter 17  Challenging Times for Mental Health

Appendix A: Quick Reference to Psychotropic Medications
Appendix B: Introduction to Epigenetics

Claire D. Advokat

Claire Advokat received her Ph.D. in physiological psychology from Rutgers University, following which she completed an NIH Postdoctoral Fellowship at the College of Physicians and Surgeons of Columbia University in New York City. She then served on the faculty of the Department of Pharmacology at the University of Illinois Health Sciences Center in Chicago. In 1989 she joined the Department of Psychology at Louisiana State University, where she served as the Faculty Senate President (2004–2005), retiring in 2012 as an emerita professor. Her research area is psychopharmacology, specifically drugs used in the treatment of psychiatric and behavioral disorders. She has published over 80 articles, and received funding for her studies from the National Institute of Drug Abuse (NIDA), the Spencer Foundation, the Board of Regents of Louisiana, the State of Louisiana, and the pharmaceutical firm NPS. She received a university teaching award in 2005, served as an ad hoc reviewer for 20 journals, and serves on the editorial board of The Journal of Attention Disorders.

Joseph E. Comaty

Joseph E. Comaty received his M.S. in experimental psychology from Villanova University; his Ph.D. in psychology with a specialization in clinical neuropsychology from the Rosalind Franklin University of Medicine and Science, in Illinois; and his postdoctoral Masters Degree in clinical psychopharmacology from Alliant University/CSPP in California. He is a licensed psychologist under the Louisiana State Board of Examiners of Psychologists (LSBEP) and a licensed medical psychologist under the Louisiana State Board of Medical Examiners. He retired from the Louisiana Department of Health and Hospitals, Office of Behavioral Health in 2013 where he was the Chief Psychologist and Medical Psychologist and Director of the Division of Quality Management. He is an adjunct assistant professor in
psychology at Louisiana State University (LSU) in Baton Rouge and serves as emeritus faculty of the Southern Louisiana Internship Consortium (SLIC) in psychology at LSU. He has served as a member and chair of the LSBEP; he is a member and current chair of the RxP Designation Committee of APA, and a site reviewer for APA’s Committee on Accreditation. He is a member of the Model Act and Regulation Revision Committee for the Association of State and Provincial Psychology Boards (ASPPB). His research is in the areas of behavior therapy, pharmacology, and clinical psychopharmacology. He is the author of over 50 articles, book chapters, and presentations. He has served on federal grant review committees
and has been a reviewer for Psychiatric Services; The Journal of Gerontology: Psychological Sciences; and the Journal of Behavioral Health Services and Research.

Robert M. Julien, Ph.D.

Robert M. Julien, M.D., received his M.S. and Ph.D. in pharmacology from the
University of Washington and his medical degree from the University of California at Irvine. His many research articles focus on the psychopharmacology of sedative and antiepileptic drugs. Formerly an associate professor of pharmacology and anesthesiology at the Oregon Health Sciences University, Dr. Julien has retired from the practice of anesthesiology and is currently a psychopharmacology consultant in Portland, Oregon.